The NICE cost-effectiveness threshold: what it is and what that means.
about
Deep Brain Stimulation for Parkinson's Disease with Early Motor Complications: A UK Cost-Effectiveness AnalysisA systematic review of studies eliciting willingness-to-pay per quality-adjusted life year: does it justify CE threshold?A Review on Cost-Effectiveness and Cost-Utility of Psychosocial Care in Cancer PatientsElectrocardiographic Screening for Prolonged QT Interval to Reduce Sudden Cardiac Death in Psychiatric Patients: A Cost-Effectiveness AnalysisUsing electronic health records to predict costs and outcomes in stable coronary artery diseaseHelping Health Care Providers and Clinical Scientists Understand Apparently Irrational Policy Decisions.A review of economic evaluation models for cardiac resynchronization therapy with implantable cardioverter defibrillators in patients with heart failurePossible Impact of Incremental Cost-Effectiveness Ratio (ICER) on Decision Making for Cancer Screening in Hong Kong: A Systematic Review.Health Economic Data in Reimbursement of New Medical Technologies: Importance of the Socio-Economic Burden as a Decision-Making CriterionGastroenterologist and nurse management of symptoms after pelvic radiotherapy for cancer: an economic evaluation of a clinical randomized controlled trial (the ORBIT study)The cost-effectiveness of deep brain stimulation for patients with treatment-resistant obsessive-compulsive disorder.Expensive cancer drugs: a comparison between the United States and the United Kingdom.The impact of preoperative patient characteristics on the cost-effectiveness of total hip replacement: a cohort study.An economic evaluation of maxillary implant overdentures based on six vs. four implantsCost-effectiveness analysis and efficient use of the pharmaceutical budget: the key role of clinical pharmacologists.Economic evaluation of lifestyle interventions for preventing diabetes and cardiovascular diseases.Clinicians' adherence versus non adherence to practice guidelines in the management of patients with sarcoma: a cost-effectiveness assessment in two European regions.Choice of generic antihypertensive drugs for the primary prevention of cardiovascular disease--a cost-effectiveness analysisStrengthening and stretching for rheumatoid arthritis of the hand (SARAH): design of a randomised controlled trial of a hand and upper limb exercise intervention--ISRCTN89936343.Cost-utility analysis of lopinavir/ritonavir versus atazanavir + ritonavir administered as first-line therapy for the treatment of HIV infection in Italy: from randomised trial to real worldEffects of family history and genetic polymorphism on the cost-effectiveness of chemoprevention with finasteride for prostate cancer.Cost-effectiveness of various interventions for newly diagnosed diabetic macular edema.How to assess the value of medicines?A lesson in business: cost-effectiveness analysis of a novel financial incentive intervention for increasing physical activity in the workplace.Routine HIV screening in Portugal: clinical impact and cost-effectiveness.Value-based reimbursement decisions for orphan drugs: a scoping review and decision framework.Pharmacogenomics--how close/far are we to practising individualized medicine for children?Health economic evaluation of type 2 diabetes mellitus: a clinical practice focused review.Cost effectiveness of the type II Boston keratoprosthesisMethods for identifying the cost-effective case definition cut-off for sequential monitoring tests: an extension of Phelps and Mushlin.Cost effectiveness of dipeptidyl peptidase-4 inhibitors for type 2 diabetes.Cost Effectiveness of Preventive Treatment for Tuberculosis in Special High-Risk Populations.Cost-effectiveness analysis of sofosbuvir compared to current standard treatment in Swiss patients with chronic hepatitis C.Cost-effectiveness of continuous subcutaneous insulin infusion versus multiple daily injections of insulin in Type 1 diabetes: a systematic review.Cost-effectiveness of norovirus vaccination in children in Peru.The economic pressures for biosimilar drug use in cancer medicineAssessment of the Economic Impact of Belimumab for the Treatment of Systemic Lupus Erythematosus in the Italian Setting: A Cost-Effectiveness AnalysisA Time-Trend Economic Analysis of Cancer Drug Trials.Cost Effectiveness of Free Access to Smoking Cessation Treatment in France Considering the Economic Burden of Smoking-Related Diseases.Cost-effectiveness of medical primary prevention strategies to reduce absolute risk of cardiovascular disease in Tanzania: a Markov modelling study
P2860
Q26779605-B0D37797-42CD-4CA1-9314-4378321E89D9Q27015133-1DA4A2E0-5F31-4CFE-B3CD-FA983069AB25Q28079810-2A610688-F94D-4235-83C8-251C88B54168Q28548272-F84206B4-A719-4BC3-94EB-E4187FE506BEQ28603610-7470FDC1-8926-4C29-A3DE-F5D42B2DB047Q30238782-41EC3BDC-2618-4188-B741-5D499ABB9F12Q30244099-58A26663-6861-4C66-A9ED-5F09E15BBC88Q30391631-7E4C8BE5-65F4-4D61-9AAD-15135A270C74Q31125979-34C8A3BA-7D9B-45E9-943C-E4167C430B69Q33638354-A6915E15-6B68-4F18-8EE6-2E63362BA6D9Q33885834-D6EA8F06-1B60-43D2-9816-5D745EA62092Q33922623-D22A0AE5-92D7-450C-873A-B6A663ECEEDDQ34071709-FE304E58-687F-45F2-BF96-82407CCD6C72Q34103042-7F6C5696-DC1D-416C-8232-0F7DA6EC2E77Q34174875-3C385FC6-B32E-4A55-BEB7-A0D3B0AA036DQ34196906-B57230BC-4FBE-4ED7-8A42-9B3D5AF8CE1FQ34210983-39DDE0C5-1749-4126-9906-74F7DF926996Q34219946-5F1712CE-43A2-4D70-AD6E-06922CFAF9C0Q34486680-BA64EEAF-7D9B-41B0-B123-380F44ADA9C9Q34608823-32886BCF-7CB4-4685-A2DD-F909621C8204Q34689090-384DE367-CF3F-486D-A0A9-0868542F28ECQ34705556-2A9DA4C1-30F7-4869-8B3C-112BFFD1B8E5Q34983557-AACCFBE7-E3A6-45D3-8580-8A3E2D36FDB1Q35013398-2E9AAA40-FD0B-4036-98BE-72543F6965EDQ35075697-0D9D0CA0-5F46-4059-ADA7-76ED7DAD04A4Q35126801-8AA43429-E25E-4E22-940D-23C3B6576F53Q35135951-950CF791-BAD9-4084-A7AB-79722F81D897Q35219344-A818D5F1-95A2-48F4-B67C-F13F85F8EC95Q35227244-4700A961-7978-4716-AE16-DEE7C5CCC244Q35529346-8F8FEE30-44DD-4D47-8357-84AF595C6F17Q35570938-097B00DF-1627-4001-92F9-22E0C79EDD5EQ35577840-C5A9B35F-3E5D-4DEF-80EB-4F65F5A5FA75Q35606843-87AA2E5E-C124-43E6-85D7-B2E823F4DC97Q35627208-6C1C0D9F-CD3D-4293-9479-625D99ECCD3EQ35706339-3F2FABDF-C7B7-41FF-89BC-D97F74EDD348Q35795204-BFC62787-7AD6-4145-848B-50EBDD0C3193Q35816153-521C268C-82C9-42A7-9796-6660EDB11A8FQ35820527-21762161-EE8D-4EEC-9F9B-6358A9A2DEC3Q35933786-EFE9E46C-E93D-4816-B9D6-F773E46EE7D8Q36019269-90357C9A-8F0A-43CE-96A4-8CD5589518AD
P2860
The NICE cost-effectiveness threshold: what it is and what that means.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The NICE cost-effectiveness threshold: what it is and what that means.
@en
The NICE cost-effectiveness threshold: what it is and what that means.
@nl
type
label
The NICE cost-effectiveness threshold: what it is and what that means.
@en
The NICE cost-effectiveness threshold: what it is and what that means.
@nl
prefLabel
The NICE cost-effectiveness threshold: what it is and what that means.
@en
The NICE cost-effectiveness threshold: what it is and what that means.
@nl
P2093
P1433
P1476
The NICE cost-effectiveness threshold: what it is and what that means.
@en
P2093
Anthony J Culyer
Christopher McCabe
Karl Claxton
P304
P356
10.2165/00019053-200826090-00004
P577
2008-01-01T00:00:00Z
P5875
P6179
1008652128